Allogene Therapeutics
ALLO
172 hedge funds and large institutions have $223M invested in Allogene Therapeutics in 2025 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 53 increasing their positions, 46 reducing their positions, and 20 closing their positions.
524% more call options, than puts
Call options by funds: $281K | Put options by funds: $45K
45% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 20
15% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 46
11% more capital invested
Capital invested by funds: $201M → $223M (+$21.7M)
1% more funds holding
Funds holding: 170 → 172 (+2)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.68% less ownership
Funds ownership: 73.06% → 72.38% (-0.68%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$3.04M |
| 2 |
PSC
Patient Square Capital
Menlo Park,
California
|
+$2.61M |
| 3 |
Goldman Sachs
New York
|
+$1.43M |
| 4 |
Primecap Management
Pasadena,
California
|
+$1.4M |
| 5 |
Jane Street
New York
|
+$1.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.88M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.45M |
| 3 |
Millennium Management
New York
|
-$2.04M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.49M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.38M |
ALLO Hedge Fund Activity: Q4 2025 in Review
172 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q4 2025, worth a combined $223M — up 11% from $201M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ALLO positions and 20 closed out — a net gain of 9 holders — while 53 added to existing stakes and 46 trimmed.
The largest buyer was Candriam SCA, opening a new position worth an estimated $3.04M. The largest seller was UBS Group, cutting an estimated $2.88M.
- 172 institutional investors held Allogene Therapeutics (ALLO) as of Q4 2025, up from 170 in Q3 2025.
- Funds reported $223M of Allogene Therapeutics stock for Q4 2025, up 11% quarter-over-quarter.
- 29 funds opened new Allogene Therapeutics positions in Q4 2025 and 20 closed out, a net change of +9 holders.
- The largest Allogene Therapeutics buyer in Q4 2025 was Candriam SCA, an estimated $3.04M added.
- The largest Allogene Therapeutics seller in Q4 2025 was UBS Group, an estimated $2.88M sold.
Based on aggregated 13F filings for Q4 2025.